American specialty pharmaceutical company headquartered in Woburn, Massachusetts, formed in 2020 when CutisPharma and Silvergate Pharmaceuticals combined and expanded in 2022 with the acquisition of Slayback Pharma. Develops and markets medicines designed for patients who have difficulty with conventional dosage forms, including ready to use oral liquids and reformulated products across cardiovascular, central nervous system, endocrine, gastrointestinal and institutional care, together with generic and complex injectable products.
Keine Kommentare verfügbar.
Bewertung & Kommentar hinterlassen